Kinisla launches €300m dairy investment programme

Kerry Dairy Ireland has rebranded as Kinisla and announced major investment. The majority farmer-owned dairy business will invest €300m over five years across nutritional ingredients, consumer foods, sustainability, and new roles.


IN Brief:

  • Kerry Dairy Ireland has relaunched as Kinisla after becoming a majority farmer-owned business.
  • The company has announced a €300m five-year investment programme across dairy ingredients, consumer foods, sustainability, and jobs.
  • The programme targets milk protein manufacturing, dairy snacking, and emissions reduction across a vertically integrated dairy platform.

Kinisla, the dairy business formerly known as Kerry Dairy Ireland, has unveiled its new corporate identity and set out a €300m five-year investment programme across its consumer foods, nutritional ingredients, and sustainability operations.

The new identity was launched in Listowel, County Kerry, following the return of majority ownership to Kerry Co-operative Creameries. The business combines milk assembly, dairy processing, nutritional ingredients, consumer brands, agribusiness services, and farmer-facing support within a vertically integrated structure.

Kinisla will use the investment programme to expand higher-value nutritional ingredients, strengthen dairy consumer brands, and support delivery of Scope 1 and Scope 2 carbon reduction targets. The business is also creating 100 roles across central and other functions over the next 12 to 24 months as it builds capacity for its next phase of expansion.

The company processed more than 1.2 billion litres of milk in 2025, with volumes rising 5.2%. Turnover increased to €1.4bn and EBITDA reached €86.8m, while nutritional ingredients recorded strong growth, particularly across milk proteins. Its ingredient base includes milk protein isolates and concentrates, protein fractions, hydrolysates, demineralised whey, base powders, cheese solutions, and speciality milk powders for dairy, bakery, and convenience food applications.

Dairy processing is increasingly being pulled toward higher-value functionality rather than bulk volume alone. Milk proteins, lactose-free systems, snacking cheese, and fortified dairy products are all creating demand for more precise processing, stronger application support, and tighter control of ingredient performance. A litre of milk can now move into multiple value chains, but only where the processor has the technology, customer access, and product development discipline to support them.

That pressure is already visible across the sector. Kerry’s Carrigaline lactase expansion underlined the growing importance of enzyme capacity for lactose-free and reduced-sugar dairy products, while protein-led dairy launches are continuing to reshape chilled and ambient formulation work. Kinisla’s investment programme fits that same direction, particularly around milk protein manufacturing technology and dairy snacking.

Farm-level sustainability data is becoming part of the processing equation as well. Kinisla’s Evolve RegenDairy programme connects the investment plan to regenerative agriculture and supplier engagement, linking milk supply, emissions reduction, and customer assurance. Dairy processors cannot separate plant investment from farm economics for long, particularly where ownership, milk price, and generational renewal sit inside the same business model.

The company’s challenge will be to turn local milk supply into a more scalable ingredient and branded-food platform without losing cost control. Nutritional ingredients demand capital, technical capability, and international customer relationships, while dairy snacking depends on packaging, portioning, cold-chain discipline, and brand consistency. Kinisla is now positioned as a farmer-owned processor with a larger manufacturing brief, where growth will depend on how effectively it connects milk supply, processing investment, and higher-value applications.


Stories for you


  • EPAX Cetoleic 2040 lowers LDL in clinical trial

    EPAX Cetoleic 2040 lowers LDL in clinical trial

    EPAX Cetoleic 2040 reduced LDL-cholesterol by 7% after eight weeks in a randomised clinical trial of overweight and obese adults, adding human data to the emerging category of marine long-chain monounsaturated fatty acids.


  • T. Hasegawa targets dairy-free flavour gap

    T. Hasegawa targets dairy-free flavour gap

    T. Hasegawa USA has launched HASEMILK, a powdered dairy-free flavour technology designed to recreate milk taste, aroma, and mouthfeel in plant-based beverages, bakery, desserts, sauces, and dry mixes.